Pasar al contenido principal

CONTRIBUCION DE FGF21 Y DE LAS ALTERACIONES DEL METABOLISMO LIPIDICO A LA DISFUNCION MIOCARDICA EN LA DIABETES MELLITUS TIPO 2.

PI17/01362

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Centro realización HOSPITAL GERMANS TRIAS I PUJOL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Link between Abdominal Obesity Indices and the Progression of Liver Fibrosis, Insights from a Population-Based Study

  • Julián, María Teresa|||0000-0003-2524-1823
  • Arteaga, Ingrid
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Pera, Guillem|||0000-0003-3188-7268
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Ruiz-Rojano, Irene
  • Casademunt-Gras, Elena
  • Chacón, Carla|||0000-0001-8524-6189
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
There is currently no available information on the correlation between abdominal obesity indices and the risk of liver fibrosis progression. We aimed to investigate the relationship between the body mass index (BMI), waist circumference (WC), and the visceral adiposity index (VAI) with the progression of liver fibrosis. The study also evaluated the association between these indices and the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and liver fibrosis. A total of 1403 subjects participated in the cross-sectional and longitudinal population-based study. Liver stiffness was assessed via transient elastography, at baseline and follow-up (median: 4.2 years). The subgroup with dysglycemia was also analyzed. In the cross-sectional study, the highest quartile of VAI, BMI ≥ 30 kg/m 2, and abdominal obesity showed significant associations with the prevalence of MASLD and liver fibrosis, as well as with fibrosis progression. However, VAI showed no association with MASLD incidence. Among the dysglycemic subjects, there was no observed association between VAI and the incidence of MASLD or the progression of fibrosis. In conclusion, the BMI, WC, and the VAI are associated with an increased risk of progression to moderate-to-advanced liver fibrosis in the general population. However, the VAI does not perform better than the BMI and WC measurement.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Choroidal thickness as predictor of subclinical carotid atherosclerosis in adults with type 1 diabetes

  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Salvador-Miras, Ignacio
  • Carbonell Puig, Marc
  • Gratacòs, Mònica|||0000-0001-7304-7289
  • Traveset, Alicia|||0000-0003-2703-326X
  • Correig Fraga, Eudald|||0000-0001-8556-0469
  • Hernández García, Marta|||0000-0003-1237-298X
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Mauricio, Didac|||0000-0002-2868-0250
Patients with Type 1 Diabetes (T1DM) have a higher risk of cardiovascular disease. This study used carotid ultrasound to identify subclinical carotid plaques and Optical Coherence Tomography (OCT) to evaluate ophthalmological markers as predictors of carotid plaque presence in 242 adults with T1DM, employing machine learning models for early risk assessment. Individuals with carotid plaques (N=67) did not show significant differences in retinal nerve fiber layer (RNFL) and ganglion cell layer (GCL) and inner plexiform layer (IPL) complex compared to those without (N=175). However, subfoveal and temporal choroidal area thickness significantly decreased in individuals with plaques (P≤0.01). Machine learning identified age, hypertension, dyslipidemia, smoking, and diabetic retinopathy as key predictors for plaque presence, while ophthalmological measures made a modest contribution. Choroidal thickness exhibited an inverse relationship with plaque risk. Despite robust accuracy and high specificity (82-85% and 92-98%, respectively), the models were overly conservative in predicting positive instances (balanced accuracy of 0.60 for the left eye and 0.71 for the right eye). If further validated, choroidal thickness could complement traditional risk factors as an early marker of CV risk in T1DM patients. Integrating this measure in specialized clinical settings could help identify individuals who may need additional cardiovascular assessments.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lipidomic analysis reveals metabolism alteration associated with subclinical carotid atherosclerosis in type 2 diabetes

  • Barranco-Altirriba, Maria|||0000-0002-1525-210X
  • Rossell, Joana|||0000-0003-1500-6379
  • Alonso, N.
  • Weber, R.J.M.
  • Ortega, Emilio|||0000-0002-2217-8905
  • Lloyd, G.R.
  • Hernandez, Marta
  • Yanes, Oscar|||0000-0003-3695-7157
  • Capellades, Jordi|||0000-0002-6502-8202
  • Winder, Catherine|||0000-0002-1648-5255
  • Junza, Alexandra
  • Falguera, Mireia|||0000-0002-7846-8952
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Dunn, Warwick B.|||0000-0001-6924-0027
  • Perera Lluna, Alexandre|||0000-0001-6427-851X
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Mauricio, Didac|||0000-0002-2868-0250
Background: Disruption of lipid metabolism contributes to increased cardiovascular risk in diabetes. Methods: We evaluated the associations between serum lipidomic profile and subclinical carotid atherosclerosis (SCA) in type 1 (T1D) and type 2 (T2D) diabetes, and in subjects without diabetes (controls) in a cross-sectional study. All subjects underwent a lipidomic analysis using ultra-high performance liquid chromatography-electrospray ionization tandem mass spectrometry, carotid ultrasound (mode B) to assess SCA, and clinical assessment. Multiple linear regression models were used to assess the association between features and the presence and burden of SCA in subjects with T1D, T2D, and controls separately. Additionally, multiple linear regression models with interaction terms were employed to determine features significantly associated with SCA within risk groups, including smoking habit, hypertension, dyslipidaemia, antiplatelet use and sex. Depending on the population under study, different confounding factors were considered and adjusted for, including sample origin, sex, age, hypertension, dyslipidaemia, body mass index, waist circumference, glycated haemoglobin, glucose levels, smoking habit, diabetes duration, antiplatelet use, and alanine aminotransferase levels. Results: A total of 513 subjects (151 T1D, 155 T2D, and 207 non-diabetic control) were included, in whom the percentage with SCA was 48.3%, 49.7%, and 46.9%, respectively. A total of 27 unique lipid species were associated with SCA in subjects with T2D, in former/current smokers with T2D, and in individuals with T2D without dyslipidaemia. Phosphatidylcholines and diacylglycerols were the main SCA-associated lipidic classes. Ten different species of phosphatidylcholines were up-regulated, while 4 phosphatidylcholines containing polyunsaturated fatty acids were down-regulated. One diacylglycerol was down-regulated, while the other 3 were positively associated with SCA in individuals with T2D without dyslipidaemia. We discovered several features significantly associated with SCA in individuals with T1D, but only one sterol could be partially annotated. Conclusions: We revealed a significant disruption of lipid metabolism associated with SCA in subjects with T2D, and a larger SCA-associated disruption in former/current smokers with T2D and individuals with T2D who do not undergo lipid-lowering treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Human ApoA-I overexpression enhances macrophage-specific reverse cholesterol transport but fails to prevent inherited diabesity in mice

  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Farré, Núria|||0000-0003-3110-6572
  • Santos, David|||0000-0003-1157-4969
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Metso, Jari
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Errico, Teresa Laura
  • Lerma Puertas, Enrique|||0000-0001-7908-2747
  • Jauhiainen, Matti|||0000-0002-3836-3785
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
Human apolipoprotein A-I (hApoA-I) overexpression improves high-density lipoprotein (HDL) function and the metabolic complications of obesity. We used a mouse model of diabesity, the db/db mouse, to examine the effects of hApoA-I on the two main functional properties of HDL, i.e., macrophage-specific reverse cholesterol transport (m-RCT) in vivo and the antioxidant potential, as well as the phenotypic features of obesity. HApoA-I transgenic (hA-I) mice were bred with nonobese control (db/+) mice to generate hApoA-I-overexpressing db/+ offspring, which were subsequently bred to obtain hA-I-db/db mice. Overexpression of hApoA-I significantly increased weight gain and the incidence of fatty liver in db/db mice. Weight gain was mainly explained by the increased caloric intake of hA-I-db/db mice (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Particle size and cholesterol content of circulating HDL correlate with cardiovascular death in chronic heart failure

  • Teis, Albert|||0000-0002-4820-0736
  • Cediel, Germán|||0000-0001-9667-7507
  • Amigó, Núria|||0000-0002-0116-9145
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Aranyó, Júlia
  • Andrés-Cordón, Joan Francesc|||0000-0003-4264-4499
  • Puig Jové, Carlos|||0000-0001-9466-2627
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Gual-Capllonch, Francisco
  • Ferrer-Sistach, Elena|||0000-0002-1795-2193
  • Vallejo Camazón, Núria|||0000-0001-6644-6767
  • Juncà Puig, Gladys|||0000-0002-4421-5658
  • López Ayerbe, Jorge|||0009-0008-8495-0877
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Domingo, Mar|||0000-0002-2935-1272
  • Santiago Vacas, Evelyn|||0000-0001-7511-406X
  • Codina, Pau|||0000-0002-2469-5711
  • Mauricio, Didac|||0000-0002-2868-0250
  • Lupón, Josep|||0000-0002-5601-9611
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Evidence regarding any association of HDL-particle (HDL-P) derangements and HDL-cholesterol content with cardiovascular (CV) death in chronic heart failure (HF) is lacking. To investigate the prognostic value of HDL-P size (HDL-Sz) and the number of cholesterol molecules per HDL-P for CV death in HF patients. Outpatient chronic HF patients were enrolled. Baseline HDL-P number, subfractions and HDL-Sz were measured using 1H-NMR spectroscopy. The HDL-C/P ratio was calculated as HDL-cholesterol over HDL-P. Endpoint was CV death, with non-CV death as the competing event. 422 patients were included and followed-up during a median of 4.1 (0-8) years. CV death occurred in 120 (30.5%) patients. Mean HDL-Sz was higher in CV dead as compared with survivors (8.39 nm vs. 8.31 nm, p < 0.001). This change in size was due to a reduction in the percentage of small HDL-P (54.6% vs. 60% for CV-death vs. alive; p < 0.001). HDL-C/P ratio was higher in the CV-death group (51.0 vs. 48.3, p < 0.001). HDL-Sz and HDL-C/P ratio were significantly associated with CV death after multivariable regression analysis (HR 1.22 [95% CI 1.01-1.47], p = 0.041 and HR 1.04 [95% CI 1.01-1.07], p = 0.008 respectively). HDL-Sz and HDL-C/P ratio are independent predictors of CV death in chronic HF patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases

  • Diarte-Añazco, E. M. G.|||0000-0003-3876-9918
  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Pérez, Antonio|||0000-0001-5528-1143
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
Sphingolipids are key signaling molecules involved in the regulation of cell physiology. These species are found in tissues and in circulation. Although they only constitute a small fraction in lipid composition of circulating lipoproteins, their concentration in plasma and distribution among plasma lipoproteins appears distorted under adverse cardiometabolic conditions such as diabetes mellitus. Sphingosine-1-phosphate (S1P), one of their main representatives, is involved in regulating cardiomyocyte homeostasis in different models of experimental cardiomyopathy. Cardiomyopathy is a common complication of diabetes mellitus and represents a main risk factor for heart failure. Notably, plasma concentration of S1P, particularly high-density lipoprotein (HDL)-bound S1P, may be decreased in patients with diabetes mellitus, and hence, inversely related to cardiac alterations. Despite this, little attention has been given to the circulating levels of either total S1P or HDL-bound S1P as potential biomarkers of diabetic cardiomyopathy. Thus, this review will focus on the potential role of HDL-bound S1P as a circulating biomarker in the diagnosis of main cardiometabolic complications frequently associated with systemic metabolic syndromes with impaired insulin signaling. Given the bioactive nature of these molecules, we also evaluated its potential of HDL-bound S1P-raising strategies for the treatment of cardiometabolic disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Outstanding improvement of the advanced lipoprotein profile in subjects with new-onset type 1 diabetes mellitus after achieving optimal glycemic control

  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Hernández García, Marta|||0000-0003-1237-298X
  • Ortega, Emilio|||0000-0002-2217-8905
  • Amigó, Núria|||0000-0002-0116-9145
  • Real, J.
  • Granado-Casas, Minerva|||0000-0003-3447-5728
  • Miñambres, Inka|||0000-0002-0899-3938
  • López, C.
  • Lecube, Albert|||0000-0001-9684-0183
  • Bermúdez-López, Marcelino|||0000-0002-3188-4158
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Mauricio, Didac|||0000-0002-2868-0250
Aims: The impact of glycemic optimization on lipoprotein subfraction parameters in apparently normolipidemic subjects with new-onset type 1 diabetes mellitus (T1D) was examined. Methods: We evaluated the serum lipid and advanced lipoprotein profiles in twenty subjects at onset of T1D and twenty non-diabetic controls by laboratory methods and 1H NMR spectroscopy shortly after diabetes diagnosis (baseline), and after achieving optimal glycemic control (HbA1c ≤ 7.0%). Results: Advanced lipoprotein analysis revealed a significant reduction from baseline in serum concentrations of triglycerides (TG), cholesterol (C), and apolipoprotein (Apo)B-containing lipoproteins of treated subjects (VLDL-TG: -21%, IDL-TG: -30%, LDL-TG: -34%, LDL-TG: -36%, P < 0.05; VLDL-C: -23%, IDL-C: -44%, LDL-C: -16%; p < 0.05). Decreased VLDL and LDL lipids were mainly attributed to concomitant reductions in the concentration of medium-sized VLDL (-36%) and medium-sized LDL (-31%) and, to a lesser extent, to large-sized LDL (-14%). Notably, proatherogenic IDL characteristics and related surrogates of atherogenicity were resolved upon achievement of optimal glycemic status. Moreover, the concentration of HDL-TG was also reduced (-18%) at follow-up. Conclusions: Our data showed that the achievement of optimal glycemic control after T1D onset corrected hidden derangements in ApoB-containing lipoproteins (particularly IDL) and HDL-TG that are related to higher cardiovascular risk in poorly controlled T1D.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Predictive Value of the Advanced Lipoprotein Profile and Glycated Proteins on Diabetic Retinopathy

  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Rossell, Joana|||0000-0003-1500-6379
  • Correig Fraga, Eudald|||0000-0001-8556-0469
  • Rojo López, Marina Idalia|||0000-0001-6748-3156
  • Amigó, Núria|||0000-0002-0116-9145
  • Hernández García, Marta|||0000-0003-1237-298X
  • Traveset, Alicia|||0000-0003-2703-326X
  • Carbonell Puig, Marc
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Mauricio, Didac|||0000-0002-2868-0250
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
This study aimed to assess whether the advanced characteristics of serum lipoprotein subclasses could better predict the risk of developing diabetic retinopathy (DR) and its severity compared to other established risk factors in subjects with type 1 (T1D) and type 2 (T2D) diabetes. This observational, cross-sectional substudy analyzed DR-related data from 309 T1D and 264 T2D subjects. The advanced lipoprotein and glycoprotein profile was determined by nuclear magnetic resonance (NMR) spectroscopy (Liposcale test). NMR analysis of lipoproteins revealed that T1D subjects with DR showed standard non-HDL particles, despite higher IDL lipid concentrations. Notably, IDL lipids were elevated in T1D subjects with worsened DR. VLDL and LDL were smaller, whereas HDL triglycerides were increased in DR compared with non-DR. On the other hand, the T2D subjects with DR showed altered characteristics in the LDL fraction, mainly revealed by a significant decrease in smaller LDL and a reduction in LDL-C. Moreover, the glycoprotein profile did not reveal significant changes among DR groups, regardless of the type of diabetes. However, lipoprotein characteristics and glycoproteins unveiled by NMR analysis did not improve the predictive value of conventional lipids or other traditional, well-established biomarkers of DR in our cohorts.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nicotinamide protects against diet-induced body weight gain, increases energy expenditure, and induces white adipose tissue beiging

  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Rodríguez-Millán, Elisabeth
  • Sebastián, David|||0000-0002-7260-3869
  • Blanco-Soto, Rosi
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Nan, Madalina Nicoleta|||0009-0001-2794-447X
  • Diarte-Añazco, E. M. G.|||0000-0003-3876-9918
  • Mato, Eugènia|||0000-0001-8121-9335
  • Lope-Piedrafita, Silvia|||0000-0002-8127-6425
  • Roglans, Núria
  • Laguna, Joan Carles|||0000-0002-2357-1186
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Mauricio, Didac|||0000-0002-2868-0250
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Villena, Josep A.|||0000-0002-2200-2985
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
Scope: Interventions that boost NAD+ availability are of potential therapeutic interest for obesity treatment. The potential of nicotinamide (NAM), the amide form of vitamin B3 and a physiological precursor of nicotinamide adenine dinucleotide (NAD)+, in preventing weight gain has not previously been studied in vivo. Other NAD+ precursors have been shown to decrease weight gain; however, their impact on adipose tissue is not addressed. Methods and results: Two doses of NAM (high dose: 1% and low dose: 0.25%) are given by drinking water to C57BL/6J male mice, starting at the same time as the high-fat diet feeding. NAM supplementation protects against diet-induced obesity by augmenting global body energy expenditure in C57BL/6J male mice. The manipulation markedly alters adipose morphology and metabolism, particularly in inguinal (i) white adipose tissue (iWAT). An increased number of brown and beige adipocyte clusters, protein abundance of uncoupling protein 1 (UCP1), mitochondrial activity, adipose NAD+, and phosphorylated AMP-activated protein kinase (P-AMPK) levels are observed in the iWAT of treated mice. Notably, a significant improvement in hepatic steatosis, inflammation, and glucose tolerance is also observed in NAM high-dose treated mice. Conclusion: NAM influences whole-body energy expenditure by driving changes in the adipose phenotype. Thus, NAM is an attractive potential treatment for preventing obesity and associated complications.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus

  • Rodríguez-Calvo, Ricardo|||0000-0001-7513-0983
  • Granado-Casas, Minerva|||0000-0003-3447-5728
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Julián, María Teresa|||0000-0003-2524-1823
  • Domingo, Mar|||0000-0002-2935-1272
  • Codina, Pau|||0000-0002-2469-5711
  • Santiago Vacas, Evelyn|||0000-0001-7511-406X
  • Cediel, Germán|||0000-0001-9667-7507
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Rossell, Joana|||0000-0003-1500-6379
  • Masana, Luis|||0000-0002-0789-4954
  • Mauricio, Didac|||0000-0002-2868-0250
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
Subjects with type 2 diabetes mellitus (T2D) are at increased risk for heart failure (HF). The cardiac-specific (FABP3) and adipose-tissue-specific (FABP4) types of the fatty acid binding proteins have been associated with both all-cause and cardiovascular (CV) mortality. The aim of this study was to explore the prognosis value of FABP3 and FABP4 in ambulatory subjects with chronic HF (CHF), with and without T2D. A prospective study involving 240 ambulatory CHF subjects was performed. Patients were followed-up for a mean of 5.78 ± 3.30 years and cause of death (if any) was recorded. Primary endpoints were defined as all-cause and CV death, and a composite endpoint that included CV death or hospitalization for HF was included as a secondary endpoint. Baseline serum samples were obtained and the serum FABP3 and FABP4 concentrations were assessed by sandwich enzyme-linked immunosorbent assay. Survival analysis was performed with multivariable Cox regressions, using Fine and Gray competing risks models when needed, to explore the prognostic value of FABP3 and FABP4 concentrations, adjusting for potential confounders. Type 2 diabetes mellitus was highly prevalent, accounting for 47.5% for total subjects with CHF. Subjects with T2D showed higher mortality rates (T2D: 69.30%; non-T2D: 50.79%, p = 0.004) and higher serum FABP3 (1829.3 (1104.9-3440.5) pg/mL vs. 1396.05 (820.3-2362.16) pg/mL, p = 0.007) and FABP4 (45.5 (27.6-79.8) ng/mL vs. 34.1 (24.09-55.3) ng/mL, p = 0.006) concentrations compared with non-T2D CHF subjects. In the whole study cohort, FABP3 was independently associated with all-cause death, and both FABP3 and FABP4 concentrations were associated with CV mortality. The predictive values of these two molecules for all-cause (FABP3: HR 1.25, 95% CI 1.09-1.44; p = 0.002. FABP4: HR 2.21, 95% CI 1.12-4.36; p = 0.023) and CV mortality (FABP3: HR 1.28, 95% CI 1.09-1.50; p = 0.002. FABP4: HR 4.19, 95% CI 2.21-7.95; p < 0.001) were only statistically significant in the subgroup of subjects with T2D. Notably, FABP4 (HR 2.07, 95% CI 1.11-3.87; p = 0.022), but not FABP3, also predicted the occurrence of the composite endpoint (death or hospitalization for HF) only in subjects with T2D. All these associations were not found in CHF subjects without T2D. Our findings support the usefulness of serum FABP3 and FABP4 concentrations as independent predictors for the occurrence of all-cause and CV mortality in ambulatory subjects with CHF with T2D.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus

  • Puig Jové, Carlos|||0000-0001-9466-2627
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Julián, María Teresa|||0000-0003-2524-1823
  • Amigó, Núria|||0000-0002-0116-9145
  • Andersen, Henrik U.
  • Ahluwalia, Tarunveer Singh|||0000-0002-7464-3354
  • Rossing, Peter|||0000-0002-1531-4294
  • Mauricio, Didac|||0000-0002-2868-0250
  • Jensen, Magnus T.
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
Subjects with Type 1 diabetes mellitus (T1DM) have an increased incidence of heart failure (HF). Several pathophysiological mechanisms have been involved in its development. The aim of this study was to analyze the potential contribution of the advanced lipoprotein profile and plasma glycosylation (GlycA) to the presence of subclinical myocardial dysfunction in subjects with T1DM. We included subjects from a Danish cohort of T1DM subjects (Thousand & 1 study) with either diastolic and/or systolic subclinical myocardial dysfunction, and a control group without myocardial dysfunction, matched by age, sex and HbA1c. All underwent a transthoracic echocardiogram and an advanced lipoprotein profile obtained by using the NMR-based Liposcale® test. GlycA NMR signal was also analyzed. Systolic dysfunction was defined as left ventricular ejection fraction ≤ 45% and diastolic dysfunction was considered as E/e'≥12 or E/e' 8-12 + volume of the left atrium.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lipidome characterisation and sex-specific differences in type 1 and type 2 diabetes mellitus

  • Barranco-Altirriba, Maria|||0000-0002-1525-210X
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Weber, Ralf J.M.|||0000-0002-8796-4771
  • Lloyd, Gavin R.|||0000-0001-7989-6695
  • Hernandez, Marta
  • Yanes, Oscar|||0000-0003-3695-7157
  • Capellades, Jordi|||0000-0002-6502-8202
  • Jankevics, Andris|||0000-0003-2095-6846
  • Winder, Catherine|||0000-0002-1648-5255
  • Falguera, Mireia|||0000-0002-7846-8952
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Dunn, Warwick B.|||0000-0001-6924-0027
  • Perera Lluna, Alexandre|||0000-0001-6427-851X
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Mauricio, Didac|||0000-0002-2868-0250
Background: In this study, we evaluated the lipidome alterations caused by type 1 diabetes (T1D) and type 2 diabetes (T2D), by determining lipids significantly associated with diabetes overall and in both sexes, and lipids associated with the glycaemic state. Methods: An untargeted lipidomic analysis was performed to measure the lipid profiles of 360 subjects (91 T1D, 91 T2D, 74 with prediabetes and 104 controls (CT)) without cardiovascular and/or chronic kidney disease. Ultra-high performance liquid chromatography-electrospray ionization mass spectrometry (UHPLC-ESI-MS) was conducted in two ion modes (positive and negative). We used multiple linear regression models to (1) assess the association between each lipid feature and each condition, (2) determine sex-specific differences related to diabetes, and (3) identify lipids associated with the glycaemic state by considering the prediabetes stage. The models were adjusted by sex, age, hypertension, dyslipidaemia, body mass index, glucose, smoking, systolic blood pressure, triglycerides, HDL cholesterol, LDL cholesterol, alternate Mediterranean diet score (aMED) and estimated glomerular filtration rate (eGFR); diabetes duration and glycated haemoglobin (HbA1c) were also included in the comparison between T1D and T2D. Results: A total of 54 unique lipid subspecies from 15 unique lipid classes were annotated. Lysophosphatidylcholines (LPC) and ceramides (Cer) showed opposite effects in subjects with T1D and subjects with T2D, LPCs being mainly up-regulated in T1D and down-regulated in T2D, and Cer being up-regulated in T2D and down-regulated in T1D. Also, Phosphatidylcholines were clearly down-regulated in subjects with T1D. Regarding sex-specific differences, ceramides and phosphatidylcholines exhibited important diabetes-associated differences due to sex. Concerning the glycaemic state, we found a gradual increase of a panel of 1-deoxyceramides from normoglycemia to prediabetes to T2D. Conclusions: Our findings revealed an extensive disruption of lipid metabolism in both T1D and T2D. Additionally, we found sex-specific lipidome changes associated with diabetes, and lipids associated with the glycaemic state that can be linked to previously described molecular mechanisms in diabetes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The double burden, type 1 diabetes and heart failure-a comprehensive review

  • Julián, María Teresa|||0000-0003-2524-1823
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
Heart failure (HF) is increasing at an alarming rate, primary due to the rising in aging, obesity and diabetes. Notably, individuals with type 1 diabetes (T1D) face a significantly elevated risk of HF, leading to more hospitalizations and increased case fatality rates. Several risk factors contribute to HF in T1D, including poor glycemic control, female gender, smoking, hypertension, elevated BMI, and albuminuria. However, early and intensive glycemic control can mitigate the long-term risk of HF in individuals with T1D. The pathophysiology of diabetes-associated HF is complex and multifactorial, and the underlying mechanisms in T1D remain incompletely elucidated. In terms of treatment, much of the evidence comes from type 2 diabetes (T2D) populations, so applying it to T1D requires caution. Sodium-glucose cotransporter 2 inhibitors have shown benefits in HF outcomes, even in non-diabetic populations. However, most of the information about HF and the evidence from cardiovascular safety trials related to glucose lowering medications refer to T2D. Glycemic control is key, but the link between hypoglycemia and HF hospitalization risk requires further study. Glycemic variability, common in T1D, is an independent HF risk factor. Technological advances offer the potential to improve glycemic control, including glycemic variability, and may play a role in preventing HF. In summary, HF in T1D is a complex challenge with unique dimensions. This review focuses on HF in individuals with T1D, exploring its epidemiology, risk factors, pathophysiology, diagnosis and treatment, which is crucial for developing tailored prevention and management strategies for this population.